One dominates kidney care with global reach, while the other leads in rehab with faster growth and higher margins. Which business model stands out for 2026?
The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether t...
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q1. Today, we are looking a...
While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor exec...
The stocks featured in this article are seeing some big returns. Over the past month, they’ve outpaced the market due to some combination of positive news, u...
DaVita’s first quarter results were met with a strongly positive market reaction, reflecting operational execution and ongoing cost control. Management attri...
When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fea...
Dialysis provider DaVita Inc. (NYSE:DVA) reported Q1 CY2026 results exceeding the market’s revenue expectations, with sales up 6% year on year to $3.42 billi...
Dialysis provider DaVita Inc. (NYSE:DVA) reported Q1 CY2026 results exceeding the market’s revenue expectations, with sales up 6% year on year to $3.42 billi...
Dialysis provider DaVita Inc. (NYSE:DVA) will be reporting results this Tuesday after market hours. Here’s what you need to know. DaVita beat analysts’ reven...
DaVita has had an impressive run over the past six months as its shares have beaten the S&P 500 by 12.5%. The stock now trades at $150.12, marking a 15.9% ga...
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ...
